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Abstract
Introduction and objective. Researchers’ opinions are divided on whether metabolic syndrome is a separate clinical entity. 
Undoubtedly, the components of the syndrome, such as abdominal obesity, hypertension, impaired glucose tolerance, 
hypertriglyceridaemia, adversely affect metabolism, bringing with it a number of consequences, including type 2 diabetes 
and cardiovascular disease which significantly impair the quality of life.  
Abbreviated description of the state of knowledge. In recent years, much attention has been paid to research on the 
prevalence of metabolic disorders in mentally ill patients. This is due to a growing awareness that some antipsychotic 
medications contribute to weight gain in patients suffering from mental illness, and consequently lead to the development 
of a number of interrelated somatic factors, such as abdominal obesity, impaired glucose tolerance, hypertriglyceridaemia, 
and hypertension. Weight gain and other metabolic syndrome components have been noticed not only in patients, but 
also in their families. This paper presents current research on the prevalence of metabolic syndrome in people with mental 
illness. An analysis of the causes of metabolic disorders in this population has been conducted, including the role of the 
hypothalamic-pituitary-adrenal axis and cortisol secretion in the development of components of metabolic syndrome.  
Conclusions. Components of the metabolic syndrome are especially observed in mentally ill people. The mechanisms 
of their formation are not fully understood. A large role in their formation besides the negative effects of antipsychotic 
medication and specific lifestyle, play a specific dysregulation of the hypothalamic-pituitary-adrenal axis. Undoubtedly, 
further research and analysis in this area is necessary.
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INTRODUCTION AND OBJECTIVE
Both mental illness and psychotic disorder entail a number of 
consequences and significantly contributes to the reduction 
in the quality of life of patients. This implies the need to adapt 
to new conditions of life, such as, among others, acceptance 
of the disease, long-term treatment, overcoming limitations, 
pain, deterioration of the socio-economic situation, 
family, and adapting to new procedures and limitations of 
treatment [1, 2].
Long-term mental illness also contributes to a number 
of somatic diseases which are often unrecognized or 
inadequately treated and lead to a significant deterioration 
in health. Life expectancy of people suffering from psychotic 
illness is lower than in the general population [3, 4]. 
Currently, it is assumed that in schizophrenia there is a 
50% increased risk of death from somatic reasons, and a 20% 
shorter survival time relative to the general population [5]. 
Numerous studies show that mortality among people with 
psychotic illness, including schizophrenia, bipolar illness, 
schizoaffective disorder, and depression is 2–3 times higher 
than in the general population, while life expectancy is 
between 13–30 years shorter compared to people without 
mental disorders. Unfortunately, this trend is still increasing, 
even in countries where the healthcare system is rated as 
good. The 60% mortality in patients suffering from mental 
illness is caused by somatic diseases [3, 6].
There are many factors leading to the deterioration of the 
health of people suffering from severe mental disorders. One of 
them is a very rare and late use of medical care due to persistent 
symptoms (positive and negative). For this reason, patients 
are not always able to define their own somatic problems. Of 
great importance, as well as a specific, is the often unhygienic 
lifestyle of people with mental illness: low physical activity, 
poor diet, smoking and addiction to drugs [6, 7]. In addition, 
some drugs used for the treatment of psychiatric disorders 
(including anti-psychotics) cause somatic changes in patients, 
and in particular contribute to the formation of metabolic 
disorders. It also appears that the specific mode of life and 
factors associated with pharmacological therapy contribute 
to increased incidence in patients with somatic disorders. 
According to the CATIE study (Clinical Anti-psychotic Trials 
for Intervention Effectiveness) and its observations, there is 
sufficient evidence to conclude that patients suffering from 
mental illness receive a lower standard of primary health care, 
and who, regardless of factors caused by their life-style and 
the effects of psychotropic medication, should be changed so 
that the access to and quality of medical services are better 
for individual patients [8, 9].
The most common somatic disorders and diseases that 
occur in people with mental illness include: obesity, metabolic 
syndrome (MetS), type 2 diabetes, cardiovascular disease 
(CVD), coronary heart disease (CHD) and cerebrovascular 
disease [3, 4].
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Abdominal obesity, impaired glucose tolerance, 
hypertriglyceridaemia and hypertension, are key factors 
that make up metabolic syndrome, otherwise known as 
’Syndrome X’, and in the past the ‘deadly quartet’ or ‘insulin 
resistance syndrome’ [10]. This syndrome was observed over 
80 years ago and has been described in more detail in 1988 
by Reaven as a syndrome of related factors (syndrome X), 
such as insulin resistance, hyperinsulinaemia, hypertension, 
dyslipidemia and glucose intolerance [11]. These are 
independent risk factors for cardiovascular complications. 
Reaven did not include obesity in the syndrome, despite the 
described connections of insulin resistance with overweight. 
He also noted that the syndrome X appeared in patients with 
normal body weight [12].
Since the 1990’s there have been a few definitions of 
metabolic syndrome. The first outlined the WHO diagnostic 
criteria [13] which proposed the assessment of insulin, or 
insulin as an essential element of the syndrome [14]. To these 
factors were included additional diagnostic criteria which 
included at least two of the following: high blood pressure, 
elevated triglycerides, low HDL cholesterol, obesity, and 
microalbuminuria [13]. The WHO definition pointed out 
that every constituent element of metabolic syndrome is 
an independent risk factor for cardiovascular disease. Due 
to the special emphasis on the diagnosis of disorders of 
carbohydrate metabolism, it also allowed the identification 
of patients at risk of type 2 diabetes [15]. The use of such 
criteria for diagnostic and epidemiological studies, however, 
required specialized implementation of the oral glucose 
tolerance test (OGTT); therefore, their use in practice has 
been relatively limited [12].
Table 1. WHO clinical criteria for metabolic syndrome [13]
Insulin 
resistance, 
identified 
by one 
of the 
following:
Type 2 diabetes
– impaired fasting glucose
– impaired glucose tolerance
– or for those with normal fasting glucose levels (<110 mg/dL), 
glucose uptake below the lowest quartile for background population 
under investigation under hyperinsulinemic, euglycemic conditions
Plus any 
two of the 
following:
– Antihypertensive medication and/or high blood pressure 
(≥140 mm Hg systolic or ≥90 mm Hg diastolic)
– Plasma triglycerides ≥150 mg/dL (≥1.7 mmol/L)
– HDL cholesterol <35 mg/dL (<0.9 mmol/L) in males or <39 mg/dL 
(1.0 mmol/L) in females
– BMI >30 kg/m2 and/or waist-hip ratio >0.9 in males, >0.85 in 
females
– Urinary albumin excretion rate ≥20 μg/min or albumin:creatinine 
ratio ≥30 mg/g
Taking into consideration these difficulties, the European 
Group for the Study of Insulin Resistance (EGIR) created 
another MetS diagnostic criteria. EGIR definition also 
emphasized the importance of insulin resistance as a 
primary etiologic factor of the metabolic syndrome, defined, 
however, by the indication of insulin. The concept of central 
obesity (abdominal) by marking only waist circumference, 
microalbuminuria was also eliminated as a criterion of little 
use in the diagnosis of metabolic syndrome [16].
Currently, WHO and EGIR definitions are primarily for 
scientific purposes and valid are those developed by the 
National Cholesterol Education NCEP-ATP III programme 
(National Cholesterol Education Program-Adult Treatment 
Panel III) and International Diabetes Federation (IDF) 
[14, 17].
The criteria for NCEP-ATP III [18] no longer included 
the indication of insulin resistance. It was decided that 
the measurement of insulin resistance and relatively low 
specific glucose tolerance test were not to be routinely 
performed in clinical practice. The definition of NCEP-
ATP III is more clinically useful because it allows easy 
diagnosis of metabolic syndrome, and in particular for 
epidemiological studies. According to the NCEP-ATP III, 
metabolic syndrome is observed in persons in whom there 
are at least 3 of the 5 components of the definition: abdominal 
obesity (males> 102 cm, females> 88 cm), fasting triglycerides 
above 150  mg/dl (≥ 1; 7 mmol/L), low HDL cholesterol 
(males <40  mg/dL (<1.04 mmol/L), females <50  mg/dL 
(<1.3 mmol/L), blood pressure above 130/85 mmHg, fasting 
glucose ≥ 110 mg/dL (≥ 6.1 mmol/L), or diagnosed diabetes 
[18, 17, 19].
Table 2. Clinical identification of metabolic syndrome by NCEP-ATP III [18]
Risk Factor Defining Level
Abdominal obesity
Males
Females
Waist circumference†
>102 cm (>40 in)
>88 cm (>35 in)
Triglycerides ≥150 mg/dL
HDL cholesterol
Males
Females
<40 mg/Dl
<50 mg/dL
Blood pressure ≥130/85 mmHg
Fasting glucose ≥110 mg/dL
Other diagnostic criteria developed by the IDF [20] are 
affordable diagnostic tools, based on the finding of abdominal 
obesity, plus 2 of 4 four components of the definition (Tab. 3). 
This definition takes into account ethnic differences in 
determining the waist circumference. Studies of metabolic 
syndrome based on the above criteria are simple and cheap, 
and the information derived from them is of great practical 
importance [21, 22, 19].
Table 3. The new International Diabetes Federation (IDF) definition of 
metabolic syndrome [20]
According to the new IDF definition, for a person to be defined as having 
metabolic syndrome they must have:
central obesity (defined as waist circumference* with ethnicity specific values: 
USA – male ≥ 102 cm, female ≥ 88 cm; Europe – male ≥ 94, female cm ≥ 80 cm) if 
BMI is >30kg/m², central obesity can be assumed and waist circumference t need 
not be measured, plus any 2 of the following 4 factors:
Raised 
triglycerides
≥ 150 mg/dL (1.7 mmol/L or specific treatment for this lipid 
abnormality
Reduced HDL 
cholesterol
< 40 mg/dL (1.03 mmol/L) in males
< 50 mg/dL (1.29 mmol/L) in femalesor specific treatment for this 
lipid abnormality
Raised blood 
pressure
systolic BP ≥ 130 or diastolic BP ≥ 85 mm Hg or treatment of 
previously diagnosed hypertension
Raised 
fasting 
plasma 
glucose
(FPG) ≥ 100 mg/dL (5.6 mmol/L), or previously diagnosed type 2 
diabetes.
If above 5.6 mmol/L or 100 mg/dL, OGTT is strongly 
recommended, but is not necessary to define the presence of the 
syndrome.
It is conclude that all definitions define metabolic syndrome 
as co-existing with related risk factors of metabolic origin 
that promote the development of cardiovascular disease with 
atherosclerotic and type 2 diabetes [10].
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In this paper a review of articles in English and Polish has 
been conducted in order to present relationships between 
mental disorders and metabolic syndrome.
Metabolic syndrome and mental disorders. In recent decades 
the profile of health problems in patients with schizophrenia 
and affective disorders has changed. While the past was 
dominated by tuberculosis and gastrointestinal infections, 
since the 1990’s cardiovascular disease, diabetes, obesity and 
metabolic syndrome are dominant. The prevalence of MetS in 
this group is 2–3 times higher than in the general population. 
Occurrence of the components is estimated as follows: obesity 
(45% -55%), hypertension (19% -58%), diabetes (10% -15%), 
lipid (25% -69%) [23, 7].
More and more often the problem of metabolic syndrome 
in people with severe mental illness is discussed. MetS 
components, such as overweight, obesity, abnormal glucose 
metabolism, dyslipidaemia and hypertension occur especially 
in patients with schizophrenia or bipolar disorder [3, 8]. 
In reviewing the literature, in particular the relationship 
between mental illness and metabolic syndrome was noted 
in the following diseases or mental states:
•	 schizophrenia and schizaffeffective disorders;
•	 mood disorders, such as bipolar, depressive and unipolar 
disorders;
•	 in states of anxiety, tension, anger, and stress.
Estimation of the prevalence of MetS in patients suffering 
from severe mental disorders encounters the same problems 
as in the group of healthy individuals. The results depend 
on the use of diagnostic criteria, racial or ethnic minorities. 
However, based on data from different parts of the world, 
it can be noted that the prevalence of metabolic syndrome 
among the mentally ill is higher than in the population 
without psychiatric disorders [8].
A Spanish study published in 2012 by Foguet et  al., 
conducted among 137 patients suffering from mental illness, 
showed that the criteria for metabolic syndrome was met, 
respectively, in 37.9% of females and 48.4% of males [24].
The prevalence of metabolic syndrome in people with 
schizophrenia is estimated to be between 19.4% – 68%. These 
differences result from the use of different diagnostic criteria 
of belonging to ethnic groups, and are evident between 
countries. In patients suffering from bipolar disorder and 
schizoaffective disorder this rate varies between 22–30% 
[8]. In a healthy population, the prevalence of metabolic 
syndrome varies between countries. Recent studies conducted 
in the USA by Ford on a group of 3.601 men and women, 
based on criteria developed by the IDF, indicate that as 
much as nearly 40% of Americans suffer from metabolic 
syndrome [25]. In Europe, the European Group for the 
Study of Insulin Resistance estimated that the prevalence 
of metabolic syndrome varies between 7% – 36% in males 
aged 40–55 years, and among females of the same age, from 
2–22% (MetS criteria according to the WHO) [26].
There are several studies on the prevalence of metabolic 
syndrome in people with psychotic illness. Extensive research 
carried out by the CATIE (Clinical Antipsychotic Trials for 
Intervention Effectiveness) in a group of 1231 people with 
schizophrenia, has shown that the prevalence of metabolic 
syndrome is equal to 35.8%, based on the diagnostic criteria 
proposed by NCEP-ATP III [34]. According to research 
by Kato et  al. in 2003, conducted in 63 patients with 
schizophrenia and 16 with bipolar disorder, as many as 60% 
of those with schizophrenia and 75% of those with affective 
disorders had metabolic syndrome (NCEP criteria-ATP III) 
[27]. Another study by the same author in 2002, carried out 
on 48 patients suffering from schizophrenia, showed the 
prevalence of metabolic syndrome at 63%, while in a group 
of Latin Americans, it was much higher and reached 74%, 
and indicated that an increase in waist circumference is 
positively correlated with metabolic syndrome in the above-
mentioned group of patients [28]. Other studies carried out 
on 98 patients in the USA and Taiwan by Litterell et  al., 
produced a somewhat different picture. In the USA, 51% 
of schizophrenia patients had  MetS, while patients in 
Taiwan, only 22% [27]. Data from Finland give yet another 
picture, as the metabolic syndrome was observed in 37% of 
schizophrenia among 35 active people [28].
A study published in December 2012 by Grover et  al., 
conducted in India in a group of 227 people suffering from 
schizophrenia, showed that the prevalence of metabolic 
syndrome ranged from 43.6% – 44.5%, depending on the 
definition of the MetS diagnostic criteria used, i.e. IDF and 
NCEP-ATP III. Interestingly, there was no difference in 
the prevalence of the metabolic syndrome according to the 
antipsychotic drugs used [29].
Bobes et al. showed that the prevalence of coronary artery 
disease and metabolic syndrome in Spanish patients with 
schizophrenia (n = 1,452) who were subjected to treatment 
with antipsychotics, was the same as in the general population, 
but who were older by about 10–15 years [30].
Many authors have suggested that abdominal obesity is 
an essential determinant of insulin resistance, resulting 
in pathophysiological changes leading to metabolic 
syndrome [27].
Individuals suffering from psychotic disorders, including 
schizophrenia, have a tendency to become overweight or 
obese. Additionally, Ryan et al. showed that the incidence 
of glucose intolerance in patients with previously untreated 
schizophrenia is 15% higher than in the healthy population 
[31]. Both type 2 diabetes and schizophrenia are disorders of 
a complex, polygenic and multifactorial model of inheritance. 
The increase in the incidence of diabetes in schizophrenic 
patients was pointed out earlier, before there appeared the 
current spread of risk factors of obesity and diabetes in 
psychiatric patients. Glucose intolerance was observed in 
patients with a first episode of the disease who did not yet 
take medication. More importantly, abnormal glucose values 
were observed in family members of patients; it is therefore 
possible that the same genetic loci are partly responsible for 
the tendency to disclose these diseases [32].
Weight gain is a common problem associated with the use 
of neuroleptics. Antipsychotic medications not only cause 
increases in body weight, they may also lead to impaired 
glucose tolerance, resulting in hyperglycaemia, diabetes, 
ketoacidosis or impact on lipid metabolism, by increasing 
low-density lipoprotein (LDL) and lowering cholesterol 
(HDL). The effect of medications differ in this respect [35].
These drugs affect the alimentary system in the 
hypothalamic tract. The operation of this system depends 
on a number of neural structures. It was found that 
antipsychotic drugs, by blocking the serotonin receptor 5-HT 
2, histamine H1 or dopamine D2, induce increased appetite 
and consequently weight gain. On the other hand, these 
drugs affect the hormonal regulation of food intake. Leptin, 
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a hormone produced by adipose tissue, has a long-lasting 
inhibitory effect on neurons in the hypothalamus hunger 
centre. It is known that in the case of constant exposure to 
leptin, hypothalamic neurons contribute to the development 
of leptin resistance. It has been shown that antipsychotic 
drugs increase the concentration of leptin in the blood and 
intensify of leptin resistance, hence the increased appetite 
and weight gain [32, 33].
Currently in clinical practice first generation drugs are 
used, otherwise known as classical druygs, e.g. perazine, 
chloroprotixen, haloperidol or sulpiride, and second-
generation drugs, such as clozapine, olanzapian, risperidone 
[34]. These drugs differ in the severity of side-effects, and the 
intensity of metabolic disorders caused by them, especially 
weight gain and changes in the carbohydrate and lipid systems 
[23]. Second-generation drugs, in addition to molindone, 
ziprasidone, and aripiprazole, cause weight gain. Especially 
noticeable is the large increase in the use of clozapine and 
olanzapine (more than 4 kg after 10 weeks of treatment), while 
in the case of first generation drugs, interference with glucose 
metabolism is noticeable after using chlorpromazine [7, 21].
It has been pointed out that in the case of use of antipsychotic 
medications, the average weight gain is noticeable during the 
first few months and is equal to 2–9 kg. The degree of weight 
gain depends on the type and not the size of the daily dose 
of medication [35].
A good example illustrating the effects of second-
generation medication and especially clozapine are tests 
by Brunero et al. in 2009. Data from operations carried out 
among 73 patients with schizophrenia suggest that as many 
as 61.6% of them had metabolic syndrome, with respect to 
the definition of IDF [38].
To better describe the impact of neuroleptics on lipid 
and glucose parameters it is worth mentioning the research 
conducted by Lindenmayer et al. in a group of 101 patients 
with schizophrenia or schizoaffective disorder. During the 14 
weeks of treatment, the patients were randomly prescribed the 
following medications: clozapine, olanzapine, haloperidol, 
risperidone. It was noted that the use of clozapine, olanzapine 
and haloperidol was associated with an increase in glycaemia, 
and olanzapine and clozapine with an increase in cholesterol 
(20.1 mg / dL and 14.7 mg / dL) [36].
Extensive research by Koro et al. showed the impact of 
neuroleptics on the formation of diabetes among 19,637 
patients with schizophrenia. It was demonstrated that 
patients taking olanzapine were more likely to develop 
diabetes than those not using antipsychotics, or using 
classical neuroleptics. The safest in this respect seems to be 
the use of risperidone, which does not affect the formation 
of diabetes, in addition to causing less body weight gain than 
olanzapine or clozapine. [37].
The mechanisms leading to metabolic consequences 
of antipsychotic drugs are still not fully understood. It is 
suggested that in this respect the role of a number of factors, 
including drug-induced increase in adipose tissue leads to 
metabolic syndrome, antagonistic effects of drugs in relation 
to the receptor for serotonin, leptin resistance, pancreatic 
beta cell damage induced dyslipidemia (produced in excess 
of fatty acids induces oxidative stress) or disruption of 
hepatocyte nuclear factor 1-alpha (HNF-1) [32].
In addition to genetic susceptibility, the effects of the use of 
some antipsychotic drugs cause development of overweight, 
obesity and susceptibility to disorders of carbohydrate 
metabolism, characterized by the effect of factors such as 
unhygienic lifestyle, poor diet, poverty, smoking, poor access 
to basic health care and poor insight into own person [3, 23, 
7, 8, 5].
In this review of research literature on the relationship 
between mood disorders and metabolic syndrome testing 
the relationship between depression and the components of 
metabolic syndrome, there emerge fasctors such as obesity 
and type 2 diabetes. However, it should be noted that the 
results in this area are not clear. Some studies have shown a 
positive association between obesity and depressive disorders, 
while others exclude the existence of such a relationship.
Pálinkás et al. checked the relationship between depressive 
disorders and type 2 diabetes (971 males and females over 
50 years of age). They pointed out that depressive symptoms 
measured by the Beck Depression Inventory were positively 
correlated with the concentration of glucose in the blood. 
At the same time, there was no relationship between the 
level of glucose in the blood serum of a greater number of 
points in the Beck Scale [39]. The same authors checked the 
relationship between obesity and depressive disorders, also 
measured by the Beck Depression Inventory (score above 
13 points), in 2, 245 people over 50 years of age. Severity of 
depressive symptoms was inversely related to body weight in 
the males but not in the females. Overweight or obese females 
in the age group 50–69 years showed more severe depression 
than females hose body mass index was normal [40].
In more detailed studies by Roberts et al. at the turn of 
1994–1999, in a group of 2,123 people aged over 50, indicated 
that there is a relationship between obesity and the severity 
of depressive symptoms. It was noted that in obese people the 
risk of developing depression increased after 5 year. It was 
also found that obesity can lead to depression, but depression 
does not increase the risk of obesity [41].
Analysis of the results of a study by Gil et al. (2003–2004) 
in a group of 795 people (477 females and 318 males) showed 
that the disclosure of depression is associated with an 
increased risk of metabolic syndrome components, such 
as hypertension, obesity, and impaired glucose tolerance. 
Metabolic syndrome was diagnosed in 32% of patients, and 
depression, on the Beka Depression Scale, in 37% (more 
common in females than in males). Males diagnosed with 
depression were more often diagnosed with abdominal 
obesity [42].
In another study published in 1993 by Gluecki et  al. 
described 30 patients with familial hypertriglyceridaemia 
and depression -15 men and 15 women, who after 54 weeks 
of intensive treatment with fibrates and diet lowering 
triglyceride levels, showed significant alleviation or complete 
resolution of the symptoms depression. According to the 
researchers, the mood improvement was made possible by 
the improvement in cerebral perfusion and oxygen supply 
to the neurons [43].
The pathomechanism of depression formation is primarily 
associated with the body’s response to stress. An essential 
element of adaptive response to stress is to stimulate the 
sympatho-adrenal system (SAS) and the hypothalamo-
pituitary axis (HPA), in conjunction with the limbic system. 
Serotonin is involved in the activation of the HPA axis stress, 
exercising control over both the same axis as the sympatho-
adrenal system. Glucocorticoids and catecholamines secreted 
in times of stress may control the activity of the HPA and 
SAS. Under the influence of excessive and chronic stressors, 
818
Annals of Agricultural and Environmental Medicine 2014, Vol 21, No 4
Urszula J Łopuszańska, Katarzyna Skórzyńska-Dziduszko, Krystyna Lupa-Zatwarnicka, Marta Makara-Studzińska. Mental illness and metabolic syndrome – a literature review
there is increased activity of the HPA axis, resulting in 
hypercortisolemia, connected not only with the development 
of depression, but also metabolic syndrome. A link that 
connects the two disorders is the high level of glucocorticoids, 
accompanying the development of adipose tissue, leading to 
insulin resistance and other components of the metabolic 
syndrome [44, 45].
In addition, it should be noted that people with depression 
tend to isolate themselves and keeping an unhealthy lifestyle: 
overeating, choosing a nutrient-poor diet, and avoidance of 
exercise. The antidepressants used also affect the body weight 
of patients [27].
When analyzing the literature on the metabolic syndrome 
in people suffering from depression, it is noted that MetS 
is accompanied by negative emotional states. Here it is 
worth mentioning a study conducted by Raikkonen et al., 
who assessed the relationship between emotions and the 
development of metabolic syndrome. In long-term studies 
conducted over several years in a group of 425 women, 
psychological risk factors such as depression, anxiety, tension, 
stress, and biological components of MetS were studied: 
plasma glucose, triglycerides and HDL cholesterol, waist 
circumference and blood pressure. It was found that the 
likelihood of developing metabolic syndrome increased in 
females characterized by high baseline levels of depression, 
tension and anger. On the other hand, the development of 
metabolic syndrome resulted in the emergence of negative 
emotions, such as anger and anxiety [7, 2, 46, 47].
Hartley et al. (2004–2009, ATP-III) conducted interesting 
research in an occupational group particularly vulnerable 
to stress – the police. Police officers are people who at the 
beginning of their service must comply with relevant health 
conditions, i.e., good physical condition and health, broadly 
defined, including mental health. However, with time, due 
to exposure to chronic stress associated with the type of 
work, their health deteriorates. It has been shown that this 
group is particularly vulnerable to diseases of the circulatory 
system. The study was conducted in two parallel groups of 
police officers from various regions of Buffalo and Spokane 
in the USA. The prevalence of metabolic syndrome was 
higher among police officers from Spokane and was 37.2% 
for males and 33.3% for females, while in the Buffalo officers 
it was 32.6% and 8.5%, respectively. The researchers assessed 
the relationship between the severity of depressive symptoms 
and the number of components of the MetS. This showed 
that there was a statistically significant positive correlation 
between the severity of depressive symptoms and the number 
of components of the metabolic syndrome in the group of 
male police officers from Spokane. This dependence increased 
with the age of the respondents. [48].
Several investigators have indicated that chronic stress 
leads to depression, which increases the risk of developing the 
metabolic syndrome and thus cardiovascular disease [42, 49].
In summary, discussion of the causes of increased risk 
of metabolic disorders in the mentally ill it is worth noting 
the role of the axis of substructure-pituitary-adrenal axis 
and cortisol secretion in situations of chronic stress in the 
development of components of MetS [27].
In times of stress, there is a distortion of the body’s 
homeostasis, which activates the hypothalamic-pituitary-
adrenal axis. In response to stress, the hypothalamus releases 
corticotropin-releasing hormone (CRH), thus stimulating the 
pituitary gland to release the adrenocorticotropic hormone 
(ACTH). This results in the synthesis and release of adrenal 
glucocorticoids, which direct the processes of metabolism 
glycogenolysis in the liver and muscles, and gluconeogenesis 
in the liver and kidneys. This allows the body to respond 
appropriately to the additional stress factors [50, 51].
In the case of patients with schizophrenia, demonstrated 
by axis dysfunction of the substructure-pituitary-adrenal 
axis in the form of hypercortisolism, this leads to increased 
accumulation of visceral fat, and impaired glucose tolerance. 
A high level of cortisol in the tissues can produce an 
image of pseudo-Cushing’s syndrome, characterized by 
abdominal obesity, hyperinsulinaemia, insulin resistance 
and hypertension [27]. Interestingly, Weber-Hamann et al. 
showed similar relationships in patients with major depressive 
disorder – 22 females with depression after menopause and 
22 healthy females aged 23 years. They found that the females 
who suffered from depression and who had elevated cortisol 
levels, were characterized by an increase in body fat and a 
higher concentration of glucose OGTT [47].
There is the hypothesis that dysregulation of the 
hypothalamic-pituitary-adrenal axis may lead to the risk of 
psychosis, and the concentration of cortisol in patients with 
schizophrenia is related to the depth of psychosis, cognitive 
deficits and changes in the brain [52]. According to Walker 
et al., the concentration of cortisol in adolescents who present 
schizotypal symptoms, which may lead to the development of 
psychosis, is the severity of psychosis one or two years later.
Similar results are observed in major depressive disorder. 
For example, it is worth mentioning the study by Goodyear 
et al. (2000), conducted in a group of adolescents aged 8–16 
years, with a high risk of depression. This showed that 
increased levels of cortisol, measured in the morning over 
several weeks, increased the risk of depression (according to 
those studied in relation to life events) [53].
DISCUSSION AND SUMMARY
People who manifest mental problems have a tendency to 
obesity, which carries a number of consequences. Increased 
body weight predisposes to disorders of glucose and lipid 
metabolism. Data on the prevalence of somatic diseases 
in people with mental illness, especially schizophrenia, 
bipolar disorder, or depression, clearly indicate that this 
group is particularly vulnerable to the diseases associated 
with metabolic disorders, such as metabolic syndrome, type 
2 diabetes, cardiovascular diseases, ischaemic heart disease, 
and cerebrovascular diseases.
Metabolic disorders in patients suffering from mental 
illnesses are caused by a number of factors, the most 
important of which are: the side-effects of antipsychotic 
medications, a specific, less active lifestyle and nutrient-poor 
diet, as well as the tendency to insulin resistance before taking 
medication. These tendencies are also noticed in healthy 
family members which may indicate a genetic disposition 
to psychotic and metabolic disorders.
The treatment of patients with mental problems is still 
symptomatic and has a number of problems, including the 
choice of the appropriate medication which, in the case 
of psychotic disorders, affect the reduction of symptoms, 
both negative and positive. Although the second generation 
medications improve reduction of the above-mentioned 
symptoms, they can also contribute to the formation of, or 
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exacerbate, the components of metabolic syndrome, such as 
weight gain, increased blood glucose levels, hyperlipidaemia, 
and resistance to insulin. Therefore, the selection of appropriate 
antipsychotic medication should take into account all aspects, 
including those related to metabolic transformation.
Both in the case of the population manifesting mental 
disorders and those who are healthy, stress is a factor 
predisposing to abdominal body fat, which contributes largely 
to the development of the components of metabolic syndrome. 
This is evidenced by reports on increased levels of cortisol, 
even before taking medications, in people with mental illness.
In the case of long-term treatment of mentally ill patients, 
not only effective medication therapy, but also the impact 
of skills aimed at reducing tension, stress, and the psycho-
education for healthy lifestyles seem to be justified.
Mortality rates among the mentally ill patients are 
particularly worrying. In recent years, knowledge about the 
effects of some antipsychotics on weight gain, as well as on 
independent from pharmacology, increased susceptibility for 
the development of metabolic disorders in people suffering 
from mental illness, has been expanded. However, despite 
significant advances in knowledge, to date there are no 
uniform rules of conduct that are specifically aimed at 
educating patients on a diet and physical activity, and would 
undoubtedly contribute to improving the quality of life of 
this particular population.
REFERENCES
1. Hansson L. Determinants of quality of life In pe ople with severe mental 
illness. Acta Psychiatr Scand Suppl. 2006; (429): 46–50.
2. Talarowska M, Florkowski A, Orzechowska A, Zbolarski K, Wysokiński 
A. Konsekwencje psychologiczne zespołu metabolicznego. Psychiatria 
w Praktyce Klinicznej, tom1. Via Medica, 2008.p.67–73 (in Polish).
3. De Hert M, Correll ChU, Bobes J, Cetkovich-Bakmas M, Cohen D, et al. 
Physical illness in patients with severe mental disorders. I. Prevalence, 
impact of medications and disparities in health care. Wolrd Psychiatry 
2011; 52–77.
4. Joukamaa M, Heliovaara M, Knekt P, Raitasalo AAR. Mental disorders 
and cause — specific mortality. Br J Psychiatry. 2001; 179: 498–502.
5. Narasimhan M, Raynor JD. Evidence-Based Perspective on Metabolic 
Syndrome and Use of Antipsychotics. Drug Benefit Trends. 2010; 22: 
77–88.
6. Roshanaei-Moghaddam B, Katon W. Premature mortality from 
general medical illnesses among persons with bipolar disorder: a 
review. Psychiatr Serv. 2009; 60: 147–156.
7. Rabe-Jabłońska J. Występowanie, chorobowość i śmiertelność z powodu 
zespołu metabolicznego u chorych na schizofrenię. Ograniczenia 
terapeutyczne i wybór właściwego leku przeciwpsychotycznego. 
Psychiatria 2006; 3(4): 148–153 (in Polish).
8. Newcomber JW. Metabolic syndrome and Mental Illness. Am J Manag 
Care. 2007;13 (7 Suppl): 170–177.
9. Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, 
Patel JK, Keefe RS, Stroup TS, Lieberman JA. The Clinical Antipsychotic 
Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: 
clinical comparison of subgroups with and without the metabolic 
syndrome. Schizophr Res. 2005; 80(1): 9–18.
10. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C. Definition 
of Metabolic Syndrome Report of the National Heart, Lung, and Blood 
Institute/American Heart Association Conference on Scientific Issues 
Related to Definition, NHLBI/AHA. Conference Proceedings http://
circ.ahajournals.org/content/109/3/433.long (access: 2013.04.07).
11. Reaven GM. Banting lecture 1988. Role of insulin resistance in human 
disease. Diabetes 1988; 37: 1595–1607.
12. Pacholczyk M, Ferenc T, Kowalski J, Zespół metaboliczny. Część 
I: Definicje i kryteria rozpoznawania zespołu metabolicznego. 
Epidemiologia oraz związek z ryzykiem chorób sercowo-naczyniowych i 
cukrzycy typu 2. Postepy Hig Med Dosw. 2008; 62: 530–542 (in Polish).
13. Alberti KG, Zimmet PZ. Definition, diagnosis and classification 
of diabetes mellitus and its complications. Part 1: diagnosis and 
classification of diabetes mellitus provisional report of a WHO 
consultation. Diabet Med. 1998; 15(7): 539–553.
14. Zawiasa A, Nowicki M. Zespół metaboliczny u pacjentów po 
transplantacji narządów unaczynionych. Postępy Nauk Medycznych 
2010; 3: 227–232 (in Polish).
15. Pawłowska J, Witkowski JM, Bryl E. Zespół metaboliczny-rys 
historyczny i współczesność; Wybrane Problemy Kliniczne. Via 
Medica, 2009.p.222–228 (in Polish).
16. Balkau B, Charles MA. Comment on the provisional report from the 
WHO consultation. European Group for the Study of Insulin Resistance 
(EGIR). Diabet Med. 1999; 16(5): 442–443.
17. Reaven GM. The metabolic syndrome: requiescat in pace. Clin Chem. 
2005; 51(6): 931–938.
18. Executive Summary of The Third Report of The National Cholesterol 
Education Program (NCEP) Expert Panel on Detection, Evaluation, 
And Treatment of High Blood Cholesterol In Adults (Adult Treatment 
Panel III). JAMA. 2001; 285(19): 2486–2497.
19. Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the 
metabolic syndrome on macrovascular and microvascular outcomes 
in type 2 diabetes mellitus: United Kingdom Prospective Diabetes 
Study 78. Circulation. 2007; 116(19): 2119–2126.
20. Alberti G, Zimmet PZ, Shaw J. Grundy SM, International Diabetes 
Federation 2006: The IDF consensus worldwide definition of the 
metabolic syndrome http://www.idf.org/webdata/docs/IDF_Meta_
def_final.pdf. (access: 2013.04.07).
21. Lieberman JA, Stroup TS,  McEvoy JP, Swartz MS, Rosenheck RA, 
Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, 
Hsiao JK. Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) Investigators, Effectiveness of Antipsychotic Drugs in Patients 
with Chronic Schizophrenia. N Engl J Med. 2005; 353(12): 1209–1223.
22. Drzycińska-Tatka B, Drab-Rybczyńska A, Kasprzaj J. Zespół 
metaboliczny – epidemia XXI wieku 2011. Hygeia Public Healt. 2011; 
46(4): 423–430 (in Polish).
23. Dudek D. Zespół metaboliczny u pacjentów ze schizofrenią. Via Medica 
2010.p.123–130 (in Polish).
24. Foguet Boreu Q, Roura Poch P, Bullón Chia A, Mauri Martin C, 
Gordo Serra N, Cecília Costa R. en representación del grupo de 
Riesgo Cardiovascular en Trastorno Mental Severo (RISCA-TMS, 
Cardiovascular risk factors, cardiovascular risk and quality of life in 
patients with a severe mental disorder). Aten Primaria. 2013; 45(3): 
141–148. doi: 10.1016/j.aprim.2012.10.010.
25. Ford ES. Prevalence of the metabolic syndrome defined by the 
International  Diabetes  Federation among adults in the U.S. 
Diabetes Care. 2005; 28(11): 2745–2749.
26. Balkau B, Charles MA, Drivsholm T, Borch-Johnsen K, Wareham N, 
et al. The European Group for the Study of Insulin Resistance (EGIR): 
Frequency of the WHO metabolic syndrome in European cohorts, and 
an alternative definition of an insulin resistance syndrome. Diabetes 
Metab. 2002; 28: 364–376.
27. Toalson P,  Saeeduddin  A, Hardy T, Kabinoff G. The  metabolic 
syndrome in patients with severe mental illness. Journal of Clinical 
Psychiatry 2004; 6(4): 152- 158.
28. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hinntikka 
J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 
2003; 64: 575–579.
29. Grover S, Aggarwal M, Dutt A, Chakrabarti S, Avasthi A, et  al. 
Prevalence of metabolic syndrome in patients with schizophrenia in 
India. Psychiatry Research 2012; 200(2–3): 1035–1037.
30. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas 
J. CLAMORS Study Collaborative Group Cardiovascular and metabolic 
risk in outpatients with schizophrenia treated with antipsychotics: 
results of the CLAMORS Study. Schizophr Res. 2007; 90(1–3): 162–173.
31. Ryan MC, Collins P, Thakore JH, Impaired fasting glucose tolerance in 
first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 
2003; 160(2): 284–289.
32. Duda-Sobczak A, Wierusz-Wysocka B. Cukrzyca a choroby psychiczne. 
Psychiatria Polska 2011, XLV(4): 589–598 (in Polish).
33. Fabio P, Polsinelli G, Borlido C, Monda M, Vincenzo De Luca. The Role 
of Leptin in Antipsychotic-Induced Weight Gain: Genetic and Non-
Genetic Factors. Journal of Obesity 2012; 7. doi:10.1155/2012/572848.
34. Meder J, Tyszkowska M, Jarema M, Araszkiewicz A, Szafrański T. 
Leki przeciwpsychotyczne w praktyce lekarza psychiatry. Leczenie 
pacjentów z rozpoznaniem schizofrenii lekoopornej. Psychiatria Polska 
2008; XLII(6): 859–873 (in Polish).
820
Annals of Agricultural and Environmental Medicine 2014, Vol 21, No 4
Urszula J Łopuszańska, Katarzyna Skórzyńska-Dziduszko, Krystyna Lupa-Zatwarnicka, Marta Makara-Studzińska. Mental illness and metabolic syndrome – a literature review
35. Rzewuska M. Zaburzenia metaboliczne związane ze stosowaniem LPP 
u chorych na schizofrenię. Psychiatria Polska 2007; XLI(4): 457–472 
(in Polish).
36. Lindenmayer JP, Czobora P, Volavka J, Citrome L, Sheitman B, McEvoy 
JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and 
cholesterol levels in Patients with schiophrenia treated with typical 
or atypical antipsychotics.Am. British Journal of Psychiatry 2003; 
160: 290–296.
37. Koro CE, Fedder DO, L’Italien GJ, et  al. An assessment of the 
independent effects of olanzapine and risperidone exposure on the 
risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 
2002; 59: 1021–1026.
38. Brunero S, Lamont S, Fairbrother G. Prevalence and predictors of 
metabolic syndrome among patients attending an outpatient clozapine 
clinic in Australia. Arch Psychiatr Nurs. 2009; 23(3): 261–268.
39. Palinkas LA, Lee PP, Barrett-Connor E. A prospective study of Type 2 
diabetes and depressive symptoms in the elderly: the Rancho Bernardo 
Study. Diabet Med. 2004; 21(11): 1185–1191.
40. Palinkas LA, Wingard DL, Barrett-Connor E. Depressive symptoms in 
overweight and obese older adults: a test of the “jolly fat” hypothesis. 
J Psychosom Res. 1996; 40(1): 59–66.
41. Roberts RE, Deleger S, Strawbridge WJ, Kaplan G. Prospective 
association between obesity and depression: evidence from the Alameda 
County Study. Int J Obes Relat Metab Disord. 2003; 27(4): 514–521.
42. Gil K, Radziwiłłowicz P, Zdrojewski T, Piwoński J, Landowski J, 
Wyrzykowski B. Relationship between the prevalence of depressive 
symptoms and metabolic syndrom. Results of the SOPKARD Project. 
Kardiol Pol. 2006; 64: 464–459.
43. Glueck C, Tieger M, Kunkel R, Tracy T, Speirs J, et al. Improvement in 
symptoms of depression and in an index of life stressors accompany 
treatment of severe hypertriglyceridemia. Biol Psychiatry 1993; 34: 
240–252.
44. Wysokiński A, Kłoszewska I. Zespół metaboliczny i zaburzenia 
depresyjne – przegląd piśmiennictwa. Psychiatria 2011; 8(2): 46–52.
45. Beszczyńska B. Molekularne podstawy zaburzeń psychicznych 
wywołanych stresem, Postępy Hig Med Dosw. 2007; 690–701 (in Polish).
46. Raikkonen K, Matthews K, Kuller L. The relationship between 
psychological risk attributes and the metabolic syndrome in healthy 
women: antecedent or consequence? Metabolism 2002; 51: 1573–1577.
47. Weber-Hamann B, Hentschel F, Kniest A. Deuschle M, Colla M, et al. 
Hypercortisolemic depression is associated with increased intra-
abdominal fat. Psychosom Med. 2002; 64: 274–327.
48. Hartley TA, Knox SS, Fekedulegn D, Barbosa-Leiker C, Violanti 
JM, et al. Association between Depressive Symptoms and Metabolic 
Syndrome in Police Officers: Results from Two Cross-Sectional Studies. 
Journal of Environmental and Public Health 2012; 9.
49. Vitaliano PP, Scanlan JM, Zhang J, Savage MV, Hirsch IB, et al. A path 
model of chronic stress, the metabolic syndrome, and coronary heart 
disease. Psychosomatic Medicine 2002; 64(3): 418–435.
50. Ganong W F, Lewin-Kowalik J (eds.). Fizjologia. PZWL, 2007.p.230–238 
(in Polish).
51. Corcoran C, Walker E, Huot R, Mittal V, Messner K, et al. The stress 
cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003; 
29: 671–692.
52. Walker E, Huot R, Mittal V, Messner K, Kestler L, et  al. The stress 
cascade and schizophrenia: etiology and onset. Schizophr. Bull. 2003; 
29: 671–692.
53. Goodyer IM, Park, RJ, Herbert J. Psychosocial and endocrine features 
of chronic first-episode major depression in 8–16 year olds. Biological 
Psychiatry 2001; 5O(5): 351–357.
821
